Inherited epidermolysis bullosa
MONDO:0019276Inherited epidermolysis bullosa (EB) encompasses a number of disorders characterized by recurrent blister formation as the result of structural fragility within the skin and selected other tissues.
Also known as: epidermolysis bullosa hereditaria, hereditary epidermolysis bullosa
37 clinical trials for this condition and its sub-types, 5 tagged with Inherited epidermolysis bullosa itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Inherited epidermolysis bullosa
-
Epidermolysis bullosa dystrophica 23 trials · 30 incl. sub-types
12 sub-types
- Recessive dystrophic epidermolysis bullosa 21 trials Sub-types →
- Generalized dominant dystrophic epidermolysis bullosa 1 trial
- Acral dystrophic epidermolysis bullosa 0 trials
- Centripetalis recessive dystrophic epidermolysis bullosa 0 trials
- Dystrophic epidermolysis bullosa pruriginosa 0 trials
- Dystrophic epidermolysis bullosa, nails only 0 trials
- Epidermolysis bullosa dystrophica Neurotrophica 0 trials
- Epidermolysis bullosa dystrophica with subcorneal cleavage 0 trials
- Localized dystrophic epidermolysis bullosa 0 trials
- Pretibial dystrophic epidermolysis bullosa 0 trials
- Recessive dystrophic epidermolysis bullosa-generalized other 0 trials
- Transient bullous dermolysis of the newborn 0 trials
-
Junctional epidermolysis bullosa 6 trials · 8 incl. sub-types
15 sub-types
- Junctional epidermolysis bullosa, non-Herlitz type 2 trials Sub-types →
- Epidermolysis bullosa, junctional 2A, intermediate 0 trials
- Epidermolysis bullosa, junctional 2B, severe 0 trials
- Epidermolysis bullosa, junctional 3A, intermediate 0 trials
- Epidermolysis bullosa, junctional 3B, severe 0 trials
- Epidermolysis bullosa, junctional 4, intermediate 0 trials
- Epidermolysis bullosa, junctional 5A, intermediate 0 trials
- Epidermolysis bullosa, junctional 6, with pyloric atresia 0 trials
- Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome 0 trials
- Junctional epidermolysis bullosa Herlitz type 0 trials
- Junctional epidermolysis bullosa inversa 0 trials
- Junctional epidermolysis bullosa with pyloric atresia 0 trials
- Laryngo-onycho-cutaneous syndrome 0 trials
- Late-onset junctional epidermolysis bullosa 0 trials
- Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome 0 trials
-
Epidermolysis bullosa simplex 5 trials
20 sub-types
- Epidermolysis bullosa simplex 1B, generalized intermediate 1 trial
- Epidermolysis bullosa simplex 1A, generalized severe 0 trials
- Epidermolysis bullosa simplex 1C, localized 0 trials
- Epidermolysis bullosa simplex 1D, generalized, intermediate or severe, autosomal recessive 0 trials
- Epidermolysis bullosa simplex 2A, generalized severe 0 trials
- Epidermolysis bullosa simplex 2B, generalized intermediate 0 trials
- Epidermolysis bullosa simplex 2C, localized 0 trials
- Epidermolysis bullosa simplex 2E, with migratory circinate erythema 0 trials
- Epidermolysis bullosa simplex 2F, with mottled pigmentation 0 trials
- Epidermolysis bullosa simplex 2d, generalized, intermediate or severe, autosomal recessive 0 trials
- Epidermolysis bullosa simplex 3, localized or generalized intermediate, with BP230 deficiency 0 trials
- Epidermolysis bullosa simplex 4, localized or generalized intermediate, autosomal recessive 0 trials
- Epidermolysis bullosa simplex 5A, Ogna type 0 trials
- Epidermolysis bullosa simplex 5B, with muscular dystrophy 0 trials
- Epidermolysis bullosa simplex 5C, with pyloric atresia 0 trials
- Epidermolysis bullosa simplex 6, generalized, with scarring and hair loss 0 trials
- Epidermolysis bullosa simplex 7, with nephropathy and deafness 0 trials
- Epidermolysis bullosa simplex with anodontia/hypodontia 0 trials
- Epidermolysis bullosa simplex with nail dystrophy 0 trials
- Suprabasal epidermolysis bullosa simplex 0 trials Sub-types →
-
Kindler syndrome 0 trials
1 sub-type
Most studied deeper sub-types
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Recruiting nowThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase 3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New gel could ease blistering for skin disorder patients
Disease control Recruiting nowThis study tests a gel called TolaSure on people aged 4 and older with epidermolysis bullosa simplex, a condition that causes fragile skin and blisters. For the first 2 months, some participants get the gel and others get a placebo; then everyone gets the gel for another 2 months…
Phase 2 • Sponsor: BioMendics, LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Gene therapy for 'Butterfly Skin' disease tracked for 15 years in major safety registry
Disease control Recruiting nowThis registry follows people with recessive dystrophic epidermolysis bullosa (RDEB) who have been treated with prademagene zamikeracel, a gene therapy made from their own skin cells and surgically applied to wounds. The study monitors long-term safety and wound healing durability…
Sponsor: Abeona Therapeutics, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Phase 1/2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy gel aims to stop skin cancer from coming back in RDEB patients
Disease control Recruiting nowThis phase 2 trial tests whether a gene therapy gel called BVEC can reduce the return of squamous cell carcinoma (a type of skin cancer) in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition that causes fragile, blistering skin. The gel is app…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Lab-Grown skin patch could heal wounds in 'Butterfly Children'
Disease control Recruiting nowThis study tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein. It aims to safely heal wounds in 9 people with recessive dystrophic epidermolysis bullosa (RDEB), a rare disease that causes fragile, blistering skin. The graft i…
Phase 1/2 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New eye drops aim to ease painful corneal scratches in rare skin disease
Disease control Recruiting nowThis study tests an eye drop called KB803 in 16 people aged 6 months and older with dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing fragile skin and recurrent corneal abrasions. Participants will receive both KB803 and a placebo in random order to see if …
Phase 3 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New gel could help heal wounds in rare skin disease
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could Cell-Derived vesicles heal skin wounds in epidermolysis bullosa?
Disease control Recruiting nowThis phase 1/2 trial tests a topical treatment called Ev.FV, made from cell-derived particles, to help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a genetic skin condition causing painful blisters. The study will enroll 20 participants with active wounds an…
Phase 1/2 • Sponsor: Isfahan University of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New gel could ease pain and heal wounds for kids with butterfly skin
Symptom relief Recruiting nowThis study tests a gel called TCP-25 on people with epidermolysis bullosa (EB), a condition that causes fragile skin and painful blisters. About 32 people aged 4 and older with certain types of EB will have two matching wounds treated—one with the study gel and one with a placebo…
Phase 2 • Sponsor: Xinnate AB • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Stanford launches study to better understand rare blistering skin disease
Knowledge-focused Recruiting nowThis study is screening people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disease that causes painful blisters and open wounds from minor skin contact. Researchers at Stanford want to learn more about the disease and the patients' cells to develop new …
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study to measure hidden toll of rare skin diseases on patients and families
Knowledge-focused Recruiting nowThis study aims to understand the full burden of 9 rare skin diseases—including physical, emotional, social, and financial challenges—on patients and their families. Researchers will use special questionnaires to track how these conditions affect daily life and care needs. About …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Does a Wound-Healing gel raise cancer risk? new study aims to find out
Knowledge-focused Recruiting nowThis study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers want to see if using Filsuvez, a birch bark extract gel that helps heal blisters, changes the risk of developing skin cancer. Participants receive standard care, …
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:06 UTC